C. P. Carden

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

David Olmos, Hendrik‐Tobias Arkenau, Joo Ern Ang et al. · Annals of Oncology · 2008 · 248 citations · Full text

Medicine, Oncology, Urology +17

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

Peter C.C. Fong, David S. Boss, C. P. Carden et al. · Journal of Clinical Oncology · 2008 · 83 citations

Medicine, Oncology, Pharmacology +17

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

Stephen J. Chapman, Ruth Blanco‐Colino, Dmitri Nepogodiev et al. · British journal of surgery · 2019 · 59 citations · Full text

Medicine, Perioperative Medicine, Surgery +14

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors

Paul Nathan, Ian Judson, AR Padhani et al. · Journal of Clinical Oncology · 2008 · 42 citations

Pharmacy, Pharmacology, Cancer Drug Toxicity Management +9

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.

C. P. Carden, E. S. Kim, Robin L. Jones et al. · Journal of Clinical Oncology · 2010 · 37 citations

Medicine, Oncology, Pharmacology +16